Literature DB >> 25804482

Rationale for combining immunotherapy with chemotherapy.

Angus G Dalgleish.   

Abstract

Immunotherapy has usually been considered as an alternative to more traditional modalities. Moreover, it has previously been felt that chemotherapy is inherently immunosuppressive and not suitable for combining with immunotherapy. In this review, the concept of combining different modalities that result in cell death, such as radiotherapy and chemotherapy, with immunotherapy is explored. Tumors actively cause immune suppression which can be reversed by their removal but when this is not possible, enhancing the immune response with nonspecific immune stimulation can enhance the response to other modalities, such as radiotherapy and chemotherapy. Additionally, several chemotherapy agents at low doses selectively inhibit regulatory and suppressor cells.

Entities:  

Keywords:  checkpoint inhibitors; chemotherapy; cytokines; immunotherapy; potential synergy; regulatory and suppressor cell inhibitors; vaccines

Mesh:

Year:  2015        PMID: 25804482     DOI: 10.2217/imt.14.111

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  15 in total

Review 1.  Present and future of cancer immunotherapy: A tumor microenvironmental perspective.

Authors:  Yu Yu; Jiuwei Cui
Journal:  Oncol Lett       Date:  2018-07-26       Impact factor: 2.967

2.  Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017.

Authors:  Peter L Stern
Journal:  Ther Adv Vaccines       Date:  2017-07-20

Review 3.  Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.

Authors:  David A Reardon; Mark R Gilbert; Wolfgang Wick; Linda Liau
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 4.  Emerging Therapies in Penile Cancer.

Authors:  Antonio Machado Alencar; Guru Sonpavde
Journal:  Front Oncol       Date:  2022-06-21       Impact factor: 5.738

5.  Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients.

Authors:  Pavla Taborska; Dmitry Stakheev; Zuzana Strizova; Katerina Vavrova; Michal Podrazil; Jirina Bartunkova; Daniel Smrz
Journal:  Med Oncol       Date:  2017-09-02       Impact factor: 3.064

6.  Metronomic paclitaxel improves the efficacy of PD-1 monoclonal antibodies in breast cancer by transforming the tumor immune microenvironment.

Authors:  Qian Chen; Rui Xia; Weiwei Zheng; Luyao Zhang; Ping Li; Xingwei Sun; Jianming Shi
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

Review 7.  NF-kappaB: Two Sides of the Same Coin.

Authors:  Bruno R B Pires; Rafael C M C Silva; Gerson M Ferreira; Eliana Abdelhay
Journal:  Genes (Basel)       Date:  2018-01-09       Impact factor: 4.096

8.  Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.

Authors:  Xiangjing Meng; Guangying Du; Liang Ye; Shanyue Sun; Qiaofeng Liu; Hongbo Wang; Wenyan Wang; Zimei Wu; Jingwei Tian
Journal:  Int J Immunopathol Pharmacol       Date:  2017-06-12       Impact factor: 3.219

9.  B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients.

Authors:  Huyang Xie; Yu Zhu; Junyu Zhang; Zheng Liu; Hangcheng Fu; Yifan Cao; Gaoxiang Li; Yijun Shen; Bo Dai; Jiejie Xu; Dingwei Ye
Journal:  BMC Cancer       Date:  2018-05-24       Impact factor: 4.430

10.  Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.

Authors:  E C Martino; G Misso; P Pastina; S Costantini; F Vanni; C Gandolfo; C Botta; F Capone; A Lombardi; L Pirtoli; P Tassone; C Ulivieri; P Tagliaferri; M G Cusi; M Caraglia; P Correale
Journal:  Cell Death Discov       Date:  2016-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.